Shots:
- The P-III trial evaluates REGEN-COV (1200mg, SC) vs PBO in a ratio (1:1) in patients who lived in the same household with COVID-19 patients diagnosed within the prior 4 days. The trial is jointly run with NIAID
- The results showed an 81.6% reduction in risk of COVID-19 during a pre-specified follow-up period b/w 2-8mos. & 81.5% reduction @8mos. after receiving REGEN-COV, no deaths in any treatment group @8mos. & no new safety signals were observed
- The US FDA has authorized the use of REGEN-COV in high-risk patients or post-exposure prophylaxis settings. Regeneron & Roche collaborated to boost the supply of Ab cocktails & Roche responsible for development & distribution outside the US
Click here to read the full press release/ article | Ref: Regeneron | Image: WRGB
The post Regeneron Reports Results of REGEN-COV (casirivimab and imdevimab) in P-III Study Against COVID-19 first appeared on PharmaShots.
